Anti Micro Albuminuric Effect of Spironolatone with or without Losartan in Diabetic type II Patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT138806211241N2

Enrollment

Registered

2012-01-18

Start date

2009-10-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

micrialbuminuria in diabetic type 2. Glomerular disorders in diabetes mellitus

Interventions

Intervention 1: Intervention groups: spironolactone 25 mg daily plus losartan 12.5 twice daily. Intervention 2: Control group: spironolactone 25 mg with placebo half tablet twice daily.

Treatment - Drugs

Placebo

Intervention groups: spironolactone 25 mg daily plus losartan 12.5 twice daily

Control group: spironolactone 25 mg with placebo half tablet twice daily

Eligibility

Sex/Gender

All

Age

35 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: This study will done in 35-75 years old diabetic patient with microalbuminuria. Exclusion criteria: 1)systolic blood pressure > 180mmHg; 2)Diastolic blood pressure > 110mmHg; 3)Serum k > 5.5 mg/dl; 4)CVA or MI in 6 month ago; 5)Treatment whit corticosteroids, NSAIDs, immunosuppressive; 6)Patients whit renovascular disease, obstructive uropathy, collagenous disease, Malignancy, alcohol users, addiction; 7)Pregnant or breast fed women; 8)HbA1C > 8%.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Measurement of urinary microalbuminuria. Timepoint: Before treatment and 12 weeks after treatment. Method of measurement: Laboratory.	—

Secondary

Measure	Time frame
Measurement of sodium. Timepoint: Before treatment, 4, 8 and 12 weeks after treatment. Method of measurement: Lablatory.;Potassium. Timepoint: Before treatment, 4, 8 and 12 weeks after treatment. Method of measurement: Laboratory.;Creatinine. Timepoint: Before treatment, 4, 8 and 12 weeks after treatment. Method of measurement: Lablatory.;Urea. Timepoint: Before treatment, 4, 8 and 12 weeks after treatment. Method of measurement: Lablatory.;Hypertension. Timepoint: Before treatment, 4, 8 and 12 weeks after treatment. Method of measurement: The barometer.	—

Measure

Time frame

Measurement of sodium. Timepoint: Before treatment, 4, 8 and 12 weeks after treatment. Method of measurement: Lablatory.;Potassium. Timepoint: Before treatment, 4, 8 and 12 weeks after treatment. Method of measurement: Laboratory.;Creatinine. Timepoint: Before treatment, 4, 8 and 12 weeks after treatment. Method of measurement: Lablatory.;Urea. Timepoint: Before treatment, 4, 8 and 12 weeks after treatment. Method of measurement: Lablatory.;Hypertension. Timepoint: Before treatment, 4, 8 and 12 weeks after treatment. Method of measurement: The barometer.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Atieh Makhlough

Mazandaran University of Medical Sciences

dr.makhloogh@mazums.ac.ir+98 15122617004

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026